Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02441686
Title Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Colorado Blood Cancer Institute Denver Colorado 80218 United States Details
Eastern Maine Medical Center Brewer Maine 04412 United States Details
Massachusetts General Hosptial Boston Massachusetts 02114 United States Details
Beth Israel Deaconess Medical Center Boston Massachusetts 02215 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Virginia Piper Cancer Institute Coon Rapids Minnesota 55433 United States Details
Virgina Piper Cancer Institute Minneapolis Minnesota 55407 United States Details
Hematology Oncology of Northern New Jersey Morristown New Jersey 07962 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field